Matches in Wikidata for { <http://www.wikidata.org/entity/Q92656620> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q92656620 description "2019 թվականի հունիսի 11-ին հրատարակված գիտական հոդված" @default.
- Q92656620 description "artículu científicu espublizáu en xunu de 2019" @default.
- Q92656620 description "im Juni 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92656620 description "scientific article published on 11 June 2019" @default.
- Q92656620 description "wetenschappelijk artikel" @default.
- Q92656620 description "наукова стаття, опублікована 11 червня 2019" @default.
- Q92656620 name "Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors" @default.
- Q92656620 name "Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors" @default.
- Q92656620 type Item @default.
- Q92656620 label "Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors" @default.
- Q92656620 label "Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors" @default.
- Q92656620 prefLabel "Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors" @default.
- Q92656620 prefLabel "Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors" @default.
- Q92656620 P1433 Q92656620-0DA52C5E-D678-4A79-9595-82E6BB042BB5 @default.
- Q92656620 P1476 Q92656620-2F3EB36F-2EA8-425F-8032-7273FDEFCA43 @default.
- Q92656620 P2093 Q92656620-85504A54-0CF1-4C2E-93F3-802EA740F270 @default.
- Q92656620 P2093 Q92656620-899C4F62-1545-491F-8037-72F2EB7E255B @default.
- Q92656620 P304 Q92656620-EB751DA7-6308-4F61-9B5D-1FF922401166 @default.
- Q92656620 P31 Q92656620-667b512c-29b9-4e95-9900-acf10eae6031 @default.
- Q92656620 P31 Q92656620-96F73F31-A956-4D7F-9BB8-7C9DD6D627D4 @default.
- Q92656620 P356 Q92656620-2A1B778C-6ABC-4BFC-8B80-E5FBE3009DA9 @default.
- Q92656620 P433 Q92656620-F0AC5950-DE9D-45FF-9388-65BB65D59BF2 @default.
- Q92656620 P478 Q92656620-A4057D8B-97F7-4A51-B3E8-2576D5FB364A @default.
- Q92656620 P577 Q92656620-BB4B650A-59FD-4C83-8DA3-EEF253D1F7E7 @default.
- Q92656620 P698 Q92656620-7B1F458B-CED1-4CD3-8543-A25441DB4DDD @default.
- Q92656620 P921 Q92656620-26CBC808-17E6-4DD7-824C-A6AA04E835B5 @default.
- Q92656620 P356 FON-2019-0021 @default.
- Q92656620 P698 31184937 @default.
- Q92656620 P1433 Q2781597 @default.
- Q92656620 P1476 "Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors" @default.
- Q92656620 P2093 "Arpita Desai" @default.
- Q92656620 P2093 "Eric J Small" @default.
- Q92656620 P304 "2337-2348" @default.
- Q92656620 P31 Q13442814 @default.
- Q92656620 P31 Q7318358 @default.
- Q92656620 P356 "10.2217/FON-2019-0021" @default.
- Q92656620 P433 "20" @default.
- Q92656620 P478 "15" @default.
- Q92656620 P577 "2019-06-11T00:00:00Z" @default.
- Q92656620 P698 "31184937" @default.
- Q92656620 P921 Q1164529 @default.